Atalay Figen, Ateşoğlu Elif Birtaş, Yıldız Semsi, Firatlı-Tuglular Tülin, Karakuş Sema, Bayık Mahmut
Department of Hematology, Baskent University School of Medicine, İstanbul, Turkey.
Department of Hematology, Kocaeli University School of Medicine, Kocaeli, Turkey.
Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):164-70. doi: 10.1016/j.clml.2014.09.005. Epub 2014 Sep 28.
Changes occur in adhesion molecules in the disease course of multiple myeloma. P-selectin glycoprotein ligand-1 (PSGL-1, CD162) works as the ligand of selectin-neutrophil adhesion molecules. The aim of the present study was to investigate the relationship between PSGL-1 expression in the bone marrow and the known prognostic factors for multiple myeloma disease, disease stage, and survival.
This research included 63 patients with multiple myeloma (26 women [41.3%]; 37 men [58.7%]). The bone marrow biopsy samples obtained at disease diagnosis for each patient were stained immunohistochemically in terms of CD162 expression using standard diagnostic immunohistochemical staining methods. The laboratory results, CD162 expression, overall survival, demographic characteristics of the disease, and the relationship between CD162 expression and the disease stage were evaluated.
Among the 63 patients included in the present study, the survival rate was 82.3% for 1 year, 73.2% for 2 years, 63.4% for 3 years, 51.7% for 4 years, 40.3% for 5 years, and 33.6% for 6 and 7 years. A statistically significant difference was not detected between the CD162 staining ratio and disease survival (P = .232). A statistically significant difference was not detected between the CD162 staining degree and survival rate (P = .184). However, the overall survival of the patients with no CD162 expression in the bone marrow was lower than that for the patients whose CD162 was stained 1, 2, and 3 degrees (12.33 ± 11.49, 28.65 ± 31.44, 37.25 ± 29.32, and 47.92 ± 45.29 months, respectively; P < .001).
In the present study, CD162 staining and the staining degree, with the other standard immunohistochemical stains, were shown to be beneficial in the diagnosis of multiple myeloma disease. However, the results did not provide information about the disease course. Studies of a larger number of patients to examine P-selectin and interleukin-6 levels are needed to investigate the disease course.
在多发性骨髓瘤的病程中，黏附分子会发生变化。P-选择素糖蛋白配体-1（PSGL-1，CD162）作为选择素-中性粒细胞黏附分子的配体发挥作用。本研究的目的是探讨骨髓中PSGL-1表达与多发性骨髓瘤已知预后因素、疾病分期及生存之间的关系。
本研究纳入63例多发性骨髓瘤患者（26例女性[41.3%]；37例男性[58.7%]）。使用标准诊断免疫组织化学染色方法，对每位患者疾病诊断时获取的骨髓活检样本进行CD162表达的免疫组织化学染色。评估实验室检查结果、CD162表达、总生存期、疾病的人口统计学特征以及CD162表达与疾病分期之间的关系。
在本研究纳入的63例患者中，1年生存率为82.3%，2年生存率为73.2%，3年生存率为63.4%，4年生存率为51.7%，5年生存率为40.3%，6年和7年生存率为33.6%。未检测到CD162染色率与疾病生存率之间存在统计学显著差异（P = 0.232）。未检测到CD162染色程度与生存率之间存在统计学显著差异（P = 0.184）。然而，骨髓中无CD162表达的患者的总生存期低于CD162染色为1度、2度和3度的患者（分别为12.33±11.49、28.65±31.44、37.25±29.32和47.92±45.29个月；P < 0.001）。
在本研究中，CD162染色及其染色程度与其他标准免疫组织化学染色一样，在多发性骨髓瘤疾病的诊断中显示出有益作用。然而，结果未提供有关疾病病程的信息。需要对更多患者进行研究以检测P-选择素和白细胞介素-6水平，从而研究疾病病程。
